Temat: octreotide - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Octreotide LAR in neuroendocrine tumours – a summary of the experience
Autorzy:: Kolasińska-Ćwikła, Agnieszka
Powiązania:: https://bibliotekanauki.pl/articles/1061844.pdf
Data publikacji:: 2017
Wydawca:: Medical Education
Tematy:: neuroendocrine tumours
octreotide LAR
somatostatin analogues
Opis:: Neuroendocrine tumours are a rare and heterogeneous group of neoplasms. Most of the patients are diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option. Somatostatin analogues have been shown to control the symptoms and growth of well-differentiated metastatic neuroendocrine tumours. Octreotide LAR is one of the treatment options.
Źródło:: OncoReview; 2017, 7, 1; 22-27
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: 58-year-old woman with pancreatic neuroendocrine tumour
Autorzy:: Kolasińska-Ćwikła, Agnieszka
Powiązania:: https://bibliotekanauki.pl/articles/1065803.pdf
Data publikacji:: 2014
Wydawca:: Medical Education
Tematy:: GEP-NET/NEN – gastroeneteropancreatic neuroendocrine tumor/neoplasm
chromogranin A
octreotide LAR
somatostatinoma
Opis:: We reported a 58-year-old woman with tumor in the tail and body of pancreas measuring 70 mm in diameter who underwent distal pancreatectomy and splenectomy. Examination of a specimen of the pancreatic mass obtained histopathological features of a well-differentiated neuroendocrine carcinoma (WHO 2000 r. NECLM group 2, MIB < 2%). Immunohistochemical staining showed that the tumor cells were positive for chromogranin and synaptophysin. The tumor was radical resected; there were 9 lymph nodes without metastases. The patient was attending routine follow-up 3 years after resection, when ultrasonography detected hepatic tumor with a low echoic area, confirmed as at least 3 lesions in CT. The patient presented with symptoms of general malaise, anorexia, weight loss, diarrhea, and diabetes mellitus. The diagnosis including of the histopathological features resected specimen and symptoms suggested a somatostatinoma. The patient denied the surgery treatment so she was treated with good clinical and biochemical (normalization of chromogranin A) response to octreotide LAR. During follow-up 4 months after, Computer Tomography showed progression. The patient refused suggested chemotherapy streptozotocin combined with doxorubicin. We continued treatment with octreotide LAR, taking into consideration lack of symptoms and stabilization in chromogranin A level, with good result and stabilization in following Computer Tomography. Somatostatinoma originates from delta cells and is a rare neoplasm, accounting for about 1% of gastroenteropancreatic endocrine neoplasms. About half of somatostatinomas originate in the pancreas, and the remainders originate in other parts of the gastrointestinal tract, mainly in the duodenum. Measurement of the plasma somatostatin concentration is useful for making a diagnosis of somatostatinoma, however is very difficult to perform this examination in our country. Successful treatment with long-acting somatostatin analogues (octreotide LAR) has been reported after progression.
Źródło:: OncoReview; 2014, 4, 2; A76-82
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Autorzy:: Witek, Przemysław
Gutowska, Marta
Powiązania:: https://bibliotekanauki.pl/articles/1064786.pdf
Data publikacji:: 2016
Wydawca:: Medical Education
Tematy:: acromegaly
growth hormone
insulin-like growth factor 1
lanreotide
long-acting somatostatin analogues
octreotide
pasireotide
somatotroph pituitary adenoma
tumour volume reduction
Opis:: Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth factor 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adenoma. The main goal of treatment is to normalise both GH and IGF-1 levels, which reduces symptoms, complications and mortality. Transsphenoidal selective adenomectomy performed by an experienced neurosurgeon is the first-line therapy. Therapy with somatostatin analogues (SSA) is used as a neoadjuvant treatment prior to surgery and in a persistent disease following the surgery. The long-acting somatostatin analogues reduce serum GH/IGF-1 levels and tumour volume. In this clinical review, mechanisms and role of 1st and 2nd generation somatostatin analogues in the treatment of patients with acromegaly are presented, with particular emphasis on the effects on somatotroph pituitary adenoma volume reduction.
Źródło:: OncoReview; 2016, 6, 4; A162-168
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 4.

Tytuł:: Analogi somatostatyny w leczeniu chorych z nawrotowymi hormonalnie nieczynnymi gruczolakami przysadki - obserwacja wstępna
Somatostatin analogs in the treatment of patients with recurrent non-functioning pituitary adenomas – preliminary observations
Autorzy:: Kunert-Radek, Jolanta
Zawada, Natalia Bożena
Pisarek, Anna
Górska-Chrząstek, Magdalena
Pawlikowski, Marek
Powiązania:: https://bibliotekanauki.pl/articles/1032603.pdf
Data publikacji:: 2012
Wydawca:: Łódzkie Towarzystwo Naukowe
Tematy:: klinicznie nieczynne hormonalnie gruczolaki przysadki
analogi somatostatyny
oktreotyd
scyntygrafia receptorowa guzów przysadki
guzy nawrotowe przysadki
clinically non-functioning pituitary adenomas
somatostatin
analogs
octreotide
receptor scintigraphy of pituitary tumours
recurrent
pituitary tumours
Opis:: Introduction: Non-functioning pituitary adenomas (NFPAs) are estimated for about 30% of all pituitary adenomas. They are diagnosed late, usually in a stadium of macroadenoma. Neurosurgery is rarely curative because of the tumour invasion of the adjacent structures. One of the therapeutic options for the patients is a somatostatin analogs therapy. To introduce such a treatment, a positive result of receptor scintigraphy is compulsory. Aim: The aim of the study was the assessment of the effectiveness of the somatostatin analogs therapy among patients with NFPAs.
Wstęp: Nieczynne hormonalnie gruczolaki przysadki (NFPAs - non-functioning pituitary adenomas), stanowią około 30% wszystkich guzów przysadki. Rozpoznawane są późno, zazwyczaj w stadium makrogruczolaka. Operacja neurochirurgiczna często nie jest radykalna ze względu na naciekanie przez guz struktur sąsiadujących. Jednym z rozważanych sposobów leczenia tych pacjentów jest stosowanie analogów somatostatyny. Wdrożenie takiego leczenia uzasadnia pozytywny wynik badania scyntygrafii receptorowej. Cel: Celem pracy była ocena efektów leczenia analogiem somatostatyny chorych z NFPAs.
Źródło:: Folia Medica Lodziensia; 2012, 39, 1; 137-146
0071-6731
Pojawia się w:: Folia Medica Lodziensia
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "octreotide" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język